A Phase 1 interventional study of SGN-40 and lenalidomide in Multiple Myeloma, sponsored by Seagen Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.
Sponsored by Seagen Inc. · Phase 1, Interventional, and Treatment
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's enrollment of 36 is below the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Seagen Inc. is the lead sponsor of 84 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: SGN-40 · Drug: lenalidomide · Drug: dexamethasone
2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
Also known as: dacetuzumab
Up to 25 mg daily of a 21-day cycle.
Also known as: Revlimid
40 mg administered weekly.
Also known as: Decadron
Adverse events and lab abnormalities.
Time frame: Within 3 weeks of final infusion of SGN-40
Best clinical response, progression-free survival, and overall survival.
Time frame: Study duration
PK profile.
Time frame: Within 3 weeks of final infusion of SGN-40
Anti-drug antibody immune responses.
Time frame: Within 3 weeks of final infusion of SGN-40
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seagen Inc.